{
    "organizations": [],
    "uuid": "fede10bcbc00ef12cff53859ffe0049c865faebf",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/14/globe-newswire-alimera-sciences-to-report-fourth-quarter-and-full-year-2017-results-on-february-28-2018.html",
    "ord_in_thread": 0,
    "title": "Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "ATLANTA, Feb. 14, 2018 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the fourth quarter and year ended December 31, 2017, after the close of the financial markets on Wednesday, February 28, 2018.\nAn accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. The call will be held at 9:00 AM ET, on Thursday, March 1, 2018. Please refer to the information below for conference call dial-in information and webcast registration.\nConference Details\nConference date: Thursday, March 1, 2018 9:00AM ET\nConference dial-in: 877-269-7756\nInternational dial-in: 201-689-7817\nConference Call Name: Alimera Sciences' Fourth Quarter 2017 Results Call\nWebcast Registration: Click Here\nFollowing the live call, a replay will be available on the Company's website, www.alimerasciences.com , under \"Investor Relations.\"\nAbout Alimera Sciences\nAlimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimeraâ€™s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com .\nFor press inquiries:\nKatie Brazel\nfor Alimera Sciences\n404-317-8361\nkbrazel@bellsouth.net\nFor investor inquiries:\nCG Capital\nfor Alimera Sciences\n877-889-1972\ninvestorrelations@cg.capital\nSource:Alimera Sciences, Inc.",
    "published": "2018-02-14T15:30:00.000+02:00",
    "crawled": "2018-02-14T17:23:12.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "atlanta",
        "globe",
        "newswire",
        "alimera",
        "science",
        "nasdaq",
        "alim",
        "leader",
        "commercialization",
        "development",
        "prescription",
        "ophthalmic",
        "pharmaceutical",
        "today",
        "announced",
        "release",
        "financial",
        "result",
        "fourth",
        "quarter",
        "year",
        "ended",
        "december",
        "close",
        "financial",
        "market",
        "wednesday",
        "february",
        "accompanying",
        "conference",
        "call",
        "hosted",
        "dan",
        "myers",
        "chief",
        "executive",
        "officer",
        "rick",
        "eiswirth",
        "president",
        "chief",
        "financial",
        "officer",
        "discus",
        "result",
        "call",
        "held",
        "et",
        "thursday",
        "march",
        "please",
        "refer",
        "information",
        "conference",
        "call",
        "information",
        "webcast",
        "registration",
        "conference",
        "detail",
        "conference",
        "date",
        "thursday",
        "march",
        "et",
        "conference",
        "international",
        "conference",
        "call",
        "name",
        "alimera",
        "science",
        "fourth",
        "quarter",
        "result",
        "call",
        "webcast",
        "registration",
        "click",
        "following",
        "live",
        "call",
        "replay",
        "available",
        "company",
        "website",
        "investor",
        "relation",
        "alimera",
        "science",
        "alimera",
        "science",
        "founded",
        "june",
        "pharmaceutical",
        "company",
        "specializes",
        "commercialization",
        "development",
        "prescription",
        "ophthalmic",
        "pharmaceutical",
        "alimera",
        "presently",
        "focused",
        "disease",
        "affecting",
        "back",
        "eye",
        "retina",
        "disease",
        "well",
        "treated",
        "current",
        "therapy",
        "affect",
        "million",
        "people",
        "aging",
        "population",
        "alimera",
        "commitment",
        "retina",
        "specialist",
        "patient",
        "manifest",
        "product",
        "development",
        "portfolio",
        "designed",
        "treat",
        "disease",
        "information",
        "please",
        "visit",
        "press",
        "inquiry",
        "katie",
        "brazel",
        "alimera",
        "science",
        "kbrazel",
        "investor",
        "inquiry",
        "cg",
        "capital",
        "alimera",
        "science",
        "investorrelations",
        "source",
        "alimera",
        "science",
        "inc"
    ]
}